Study Condition(s): Soft Tissue Sarcoma

A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma (ANNOUNCE-2)

Study Alias: JGDL

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02659020 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The main purpose of this study is to evaluate the safety and efficacy of two anti-cancer drugs (gemcitabine and docetaxel) with and without the study drug known as olaratumab in participants with advanced soft tissue sarcoma (STS) or STS that has spread to another part(s) of the body.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

16+ years

Time Commitment

Your participation could last >12 months depending on how you and your tumor respond.
  • Participant must have completed all previous therapies more than 4 weeks before the start of the study

  • Participant must be willing to provide tumor tissue

  • Participant must not have had more than 2 prior lines of systemic therapies (neoadjuvant and adjuvant therapies will not be counted)

  • Participant must not be diagnosed with gastrointestinal stromal tumor (GIST) or Kaposi sarcoma

  • Participant must not have active central nervous system or brain metastasis at the start of the study

  • Participant must not have received prior treatment with gemcitabine, docetaxel and/or olaratumab (this includes participants previously enrolled in I5B-MC-JGDJ (NCT02451943)

  • Participant must not have planned elective surgery or will require surgery during study participation

  • Female participants must not be pregnant or breastfeeding

  • Participant must not have active fungal, bacterial, and/or known viral infection including HIV or viral (A, B, or C) hepatitis

Where to Participate

50 locations are currently available of 50 planned
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.